HomeCompareSGEN vs EPRT

SGEN vs EPRT: Dividend Comparison 2026

SGEN yields 0.87% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $42.5K in total portfolio value
10 years
SGEN
SGEN
● Live price
0.87%
Share price
$228.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$92.54
Full SGEN calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — SGEN vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGENEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGEN + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGEN pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGEN
Annual income on $10K today (after 15% tax)
$74.32/yr
After 10yr DRIP, annual income (after tax)
$78.66/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $10,835.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGEN + EPRT for your $10,000?

SGEN: 50%EPRT: 50%
100% EPRT50/50100% SGEN
Portfolio after 10yr
$42.1K
Annual income
$6,466.63/yr
Blended yield
15.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

SGEN
Analyst Ratings
14
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$171.82
-24.9% upside vs current
Range: $120.00 — $222.00
Altman Z
23.3
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGEN buys
0
EPRT buys
0
No recent congressional trades found for SGEN or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGENEPRT
Forward yield0.87%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$20.9K$63.4K
Annual income after 10y$92.54$12,840.73
Total dividends collected$902.00$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$171.82$35.50

Year-by-year: SGEN vs EPRT ($10,000, DRIP)

YearSGEN PortfolioSGEN Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,787$87.44$11,205$505.18$418.00EPRT
2$11,631$88.15$12,672$682.46$1.0KEPRT
3$12,534$88.82$14,490$930.48$2.0KEPRT
4$13,500$89.46$16,786$1,282.69$3.3KEPRT
5$14,536$90.05$19,753$1,791.56$5.2KEPRT
6$15,644$90.62$23,677$2,541.64$8.0KEPRT
7$16,830$91.14$29,008$3,672.99$12.2KEPRT
8$18,100$91.64$36,463$5,425.08$18.4KEPRT
9$19,459$92.11$47,238$8,221.57$27.8KEPRT
10$20,913$92.54$63,385$12,840.73$42.5KEPRT

SGEN vs EPRT: Complete Analysis 2026

SGENStock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Full SGEN Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this SGEN vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGEN vs SCHDSGEN vs JEPISGEN vs OSGEN vs KOSGEN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.